Liotrix (Thyrolar) - Comprehensive Research Paper

Document Information

• Paper Number: 48 of 76
• Category: Thyroid Hormone Replacement - Combination Products
• Last Updated: 2025-12-26
• Status: DISCONTINUED IN US (December 2018)

1. Summary

Liotrix is a synthetic combination thyroid hormone preparation containing both levothyroxine (T4) and liothyronine (T3) in a fixed 4:1 ratio by weight. Marketed in the United States as Thyrolar from 1956 until its discontinuation in December 2018, liotrix was designed to provide both thyroid hormones in a physiological ratio, theoretically mimicking the thyroid gland's natural hormone output.

CRITICAL STATUS: Thyrolar was discontinued in December 2018 by Allergan (now AbbVie) due to business reasons, not safety concerns. It is NO LONGER AVAILABLE in the United States.

The medication was FDA-approved for the treatment of hypothyroidism and thyroid-stimulating hormone (TSH) suppression in thyroid cancer. Liotrix was formulated with the intention of providing the benefits of both T4 (the primary circulating thyroid hormone and prohormone) and T3 (the biologically active hormone responsible for most thyroid effects at the cellular level).

The discontinuation of Thyrolar left patients who preferred combination thyroid therapy with limited options in the US market. While levothyroxine monotherapy remains the standard of care endorsed by major endocrinology societies, some patients and practitioners believed combination therapy provided superior symptomatic relief, though clinical evidence supporting this remains limited and inconsistent.

In Europe, liotrix remains available as Novothyral (Merck KGaA), providing ongoing access for patients in those markets. The European product maintains the same 4:1 T4:T3 ratio but uses different absolute strengths than the discontinued US formulation.

Key Characteristics:

• Generic Name: Liotrix
• US Brand Name: Thyrolar (DISCONTINUED December 2018)
• European Brand Name: Novothyral (still available)
• FDA Approval: 1956
• Manufacturer (US): Forest Pharmaceuticals, later Allergan
• Drug Class: Synthetic thyroid hormone combination
• T4:T3 Ratio: 4:1 by weight
• Controlled Substance: No
• Pregnancy Category: A (when used appropriately for hypothyroidism)
• Current US Availability: NONE - Product discontinued

Goal Relevance:

• Managing hypothyroidism to improve energy levels and reduce fatigue
• Supporting thyroid function for better metabolism and weight management
• Enhancing cognitive function and mental clarity by optimizing thyroid hormone levels
• Improving overall well-being for those who feel better on combination thyroid therapy
• Assisting in thyroid hormone balance for individuals with impaired T4-to-T3 conversion
• Providing an alternative for patients seeking combination therapy for thyroid health

2. Mechanism of Action

Liotrix provides exogenous thyroid hormones that replace or supplement endogenous thyroid hormone production, acting through the same physiological pathways as naturally produced hormones.

Thyroid Hormone Physiology

Levothyroxine (T4) Component:

• Functions primarily as a prohormone requiring conversion to T3 for biological activity
• Contains four iodine atoms (tetraiodothyronine)
• Accounts for approximately 80-90% of thyroid gland hormone output
• Long half-life (~6-7 days) provides stable serum concentrations
• Converted to T3 by tissue deiodinase enzymes (primarily Type 1 and Type 2)
• Type 1 deiodinase (D1): Present in liver, kidney, thyroid; generates circulating T3
• Type 2 deiodinase (D2): Present in brain, pituitary, brown fat, skeletal muscle; provides local T3
• Can also be converted to reverse T3 (rT3) by Type 3 deiodinase, an inactive metabolite

Liothyronine (T3) Component:

• The biologically active thyroid hormone
• Contains three iodine atoms (triiodothyronine)
• Approximately 3-5 times more potent than T4 at thyroid receptors
• Shorter half-life (~2.5 days) with more variable serum levels
• Directly binds to nuclear thyroid hormone receptors without requiring conversion
• Provides approximately 20% of total body T3 (80% from T4 conversion)

Cellular Mechanism

Nuclear Receptor Binding:

1. T3 enters cells through specific membrane transporters (MCT8, MCT10, OATP1C1)
2. T3 binds to nuclear thyroid hormone receptors (TRα and TRβ)
3. Receptor-hormone complex binds thyroid response elements (TREs) on DNA
4. Transcription of target genes is activated or repressed
5. Protein synthesis leads to metabolic effects

Metabolic Effects:

• Basal Metabolic Rate: Increases oxygen consumption and heat production
• Carbohydrate Metabolism: Enhances glucose absorption, gluconeogenesis, and glycolysis
• Lipid Metabolism: Increases lipolysis, cholesterol clearance, and LDL receptor expression
• Protein Metabolism: At physiologic levels, promotes protein synthesis; excess causes catabolism
• Cardiovascular: Increases heart rate, contractility, and cardiac output
• Neurological: Essential for brain development and cognitive function
• Growth: Synergizes with growth hormone for normal development

Rationale for Combination Therapy

Theoretical Advantages:

• Direct T3 supplementation bypasses deiodinase-dependent conversion
• May benefit patients with impaired T4-to-T3 conversion (polymorphisms in DIO1, DIO2 genes)
• Fixed ratio maintains predictable T4:T3 relationship
• Some patients report improved well-being on combination therapy

Limitations:

• 4:1 ratio does not match normal thyroid secretion ratio (~14:1 T4:T3)
• T3 component causes fluctuating serum T3 levels (peaks and troughs)
• No consistent evidence of superiority over T4 monotherapy in clinical trials
• T3 peaks may cause transient hyperthyroid symptoms

Pituitary Feedback

Both T4 and T3 provide negative feedback to the hypothalamic-pituitary-thyroid axis:

• T3 is the primary feedback signal at the pituitary
• Suppresses TSH secretion from anterior pituitary
• T4 is converted to T3 within pituitary thyrotrophs by local D2
• Exogenous T3 in liotrix contributes directly to pituitary feedback
• May result in lower TSH levels compared to equivalent T4 monotherapy doses

3. FDA-Approved Indications

Liotrix (Thyrolar) was FDA-approved in 1956 for the following indications. Note: These indications are historical as the product is discontinued in the US.

Primary Indications (Historical)

1. Hypothyroidism - Replacement or Supplemental Therapy

Used in conditions including:

• Primary hypothyroidism (thyroid gland failure)
• Secondary hypothyroidism (pituitary TSH deficiency)
• Tertiary hypothyroidism (hypothalamic TRH deficiency)
• Post-thyroidectomy hypothyroidism
• Post-radioactive iodine ablation hypothyroidism
• Congenital hypothyroidism (cretinism) - though T4 monotherapy preferred
• Myxedema and myxedema coma (though IV T4 or T3 typically preferred for emergencies)

2. Pituitary TSH Suppression

• Prevention of thyroid cancer recurrence (differentiated thyroid cancer)
• Management of thyroid nodules (largely replaced by individualized approaches)
• Goiter suppression (simple, nodular, or multinodular non-toxic goiter)

Off-Label Uses (Historical)

1. Treatment-Resistant Depression (Adjunctive)

• T3 augmentation studied more extensively than combination T4/T3
• Limited evidence for liotrix specifically

2. Euthyroid Sick Syndrome

• Not recommended by guidelines
• Some practitioners used in critically ill patients with low T3 syndrome

3. Subclinical Hypothyroidism

• Standard treatment remains levothyroxine monotherapy if treatment warranted
• Liotrix provided no documented advantage

Current Standard of Care

Following Thyrolar's discontinuation, major endocrinology society guidelines continue to recommend:

• First-line therapy: Levothyroxine (T4) monotherapy
• Combination therapy (T4 + T3): Not routinely recommended
• If combination desired: Separate levothyroxine and liothyronine products in individualized ratios

The American Thyroid Association (ATA), European Thyroid Association (ETA), and American Association of Clinical Endocrinologists (AACE) maintain that:

1. Evidence does not support routine use of combination therapy
2. Levothyroxine monotherapy adequately treats most patients
3. Some patients may benefit from combination therapy, but patient selection criteria remain undefined
4. If combination therapy is used, T4:T3 ratios of 13:1 to 20:1 may be more physiological than the 4:1 ratio in liotrix

4. Dosing and Administration

IMPORTANT: These are historical dosing guidelines for a discontinued product. Current patients requiring combination thyroid therapy must use separate levothyroxine and liothyronine products.

Thyrolar Strengths (Historical - Discontinued)

European Formulation (Novothyral - Still Available)

Note: Novothyral uses 5:1 ratio (not 4:1 like Thyrolar) and different absolute strengths.

Historical Dosing Guidelines

Initial Dosing - Hypothyroidism:

• Adults (healthy, <50 years): Thyrolar-½ to Thyrolar-1 (25-50 mcg T4/6.25-12.5 mcg T3) daily
• Adults (>50 years or cardiac disease): Thyrolar-¼ (12.5 mcg T4/3.1 mcg T3) daily
• Severe or long-standing hypothyroidism: Start with Thyrolar-¼, increase gradually
• Myxedema coma: Liotrix not recommended; use IV levothyroxine or liothyronine

Maintenance Dosing:

• Typical range: Thyrolar-1 to Thyrolar-2 (50-100 mcg T4/12.5-25 mcg T3) daily
• Titration interval: Every 2-4 weeks based on clinical response and TSH
• TSH target: 0.5-2.0 mIU/L for primary hypothyroidism (individualized)

TSH Suppression (Thyroid Cancer):

• Higher doses to achieve TSH <0.1 mIU/L or undetectable
• Thyrolar-2 to Thyrolar-3 typically required
• Balance suppression benefits against cardiovascular and bone risks

Administration

Timing:

• Once daily dosing, preferably in the morning
• Take on empty stomach, 30-60 minutes before breakfast
• Alternative: Consistent timing at bedtime (4+ hours after last meal)

Food and Drug Interactions:

• Calcium, iron, antacids: Separate by 4 hours (reduce absorption)
• Coffee: May reduce absorption; take medication 60 minutes before
• High-fiber foods: May reduce absorption

Conversion from Levothyroxine Monotherapy: When patients switched from levothyroxine to Thyrolar:

• Reduce T4 equivalent slightly to account for T3 potency
• Example: Patient on 100 mcg levothyroxine → Thyrolar-1 (50 mcg T4 + 12.5 mcg T3)
• T3 mcg is approximately 3-4 times as potent as T4 mcg
• Monitor closely for hyperthyroid symptoms during transition

Special Dosing Considerations

Pediatric (Historical):

• Not typically used; levothyroxine monotherapy preferred
• If used: Dose based on body weight with careful monitoring

Pregnancy:

• Thyroid hormone requirements typically increase 25-50%
• Separate products allow more precise titration
• Weekly TSH monitoring in first trimester recommended

Elderly/Cardiac Disease:

• Start at lowest dose (Thyrolar-¼)
• Increase slowly (every 4-6 weeks)
• Monitor for angina, arrhythmias, heart failure exacerbation

5. Pharmacokinetics

Absorption

Levothyroxine (T4) Component:

• Oral bioavailability: 40-80% (fasting state)
• Peak serum concentration (Tmax): 2-4 hours post-dose
• Absorption occurs primarily in jejunum and upper ileum
• Absorption reduced by food (especially fiber), calcium, iron, coffee

Liothyronine (T3) Component:

• Oral bioavailability: ~95% (near complete absorption)
• Peak serum concentration (Tmax): 2-3 hours post-dose
• More rapid and complete absorption than T4
• Less affected by food and mineral interactions

Combined Product:

• The T3 component produces early peaks in serum T3 levels
• T4 absorption and conversion provides sustained T3 supply
• Fluctuation pattern differs from T4 monotherapy

Distribution

Levothyroxine (T4):

• Volume of distribution: ~10-12 L (limited extravascular distribution)
• Protein binding: >99%
  • Thyroxine-binding globulin (TBG): ~70-75%
  • Transthyretin (prealbumin): ~15-20%
  • Albumin: ~5-10%
• Free T4 (unbound, biologically available): ~0.02-0.03%

Liothyronine (T3):

• Volume of distribution: ~40 L (greater tissue penetration)
• Protein binding: >99%
  • TBG: ~80%
  • Albumin: ~15%
  • Transthyretin: ~5%
• Free T3 (unbound): ~0.3% (10x higher free fraction than T4)

Metabolism

Levothyroxine (T4):

• Primary pathway: Deiodination to T3 (active) or rT3 (inactive)
• Type 1 deiodinase (D1): Liver, kidney → circulating T3
• Type 2 deiodinase (D2): Brain, pituitary, muscle → local T3
• Type 3 deiodinase (D3): Placenta, CNS → rT3 (inactivation)
• Secondary pathways: Conjugation (glucuronidation, sulfation), deamination, decarboxylation

Liothyronine (T3):

• Deiodination to T2 (diiodothyronine)
• Conjugation in liver
• Deamination and decarboxylation
• No conversion to T4 occurs

Elimination

Levothyroxine (T4):

• Half-life: 6-7 days (euthyroid state)
  • Hypothyroid: 9-10 days (prolonged)
  • Hyperthyroid: 3-4 days (shortened)
• Steady state: 4-6 weeks
• Excretion: Primarily fecal (conjugated metabolites via bile)
• Renal excretion: ~20% (as conjugates)

Liothyronine (T3):

• Half-life: ~2.5 days (range 1-2.5 days)
  • Significantly shorter than T4
  • Contributes to fluctuating serum levels
• Steady state: 1-2 weeks
• Excretion: Fecal and renal (similar pathways to T4)

Clinical Implications of Pharmacokinetics

T3 Fluctuations:

• Single daily dosing of liotrix produces T3 peaks 2-4 hours post-dose
• T3 levels may exceed normal range transiently
• May cause palpitations, anxiety, or tremor during peak
• Some practitioners split liotrix dosing (though not FDA-approved approach)

T4 Stability:

• T4 component provides stable background hormone levels
• Long half-life maintains consistent tissue T4 availability
• Peripheral conversion to T3 continues between doses

Laboratory Testing Timing:

• TSH: Reliable at any time relative to dosing
• Free T4: Relatively stable; timing less critical
• Free T3: Levels vary significantly with timing
  • Peak: 2-4 hours post-dose (may be elevated)
  • Trough: Before morning dose (better for assessment)
  • Optimal timing: 12-24 hours post-dose or pre-dose trough

6. Side Effects and Adverse Reactions

Side effects of liotrix are generally manifestations of thyroid hormone excess (hyperthyroidism/thyrotoxicosis) and are typically dose-related. The T3 component may cause more prominent symptoms during peak serum levels compared to levothyroxine monotherapy.

Common Side Effects (≥1%)

Cardiovascular:

• Palpitations (more common due to T3 peaks)
• Tachycardia (resting heart rate >100 bpm)
• Increased pulse pressure
• Hypertension (typically systolic)

Neurological/Psychiatric:

• Nervousness and anxiety
• Tremor (fine hand tremor)
• Insomnia and sleep disturbances
• Headache
• Irritability
• Emotional lability

Gastrointestinal:

• Increased appetite
• Diarrhea or increased bowel frequency
• Nausea (less common)
• Abdominal cramps

Metabolic:

• Heat intolerance
• Excessive sweating (diaphoresis)
• Weight loss (despite adequate caloric intake)
• Fever (with significant excess)

Musculoskeletal:

• Muscle weakness
• Muscle cramps
• Tremor

Dermatological:

• Warm, moist skin
• Hair loss (usually transient during initiation)
• Flushing

Serious Adverse Reactions

Cardiovascular Events:

• Angina pectoris (especially in patients with coronary artery disease)
• Arrhythmias:
  • Atrial fibrillation (particularly in elderly)
  • Premature ventricular contractions
  • Supraventricular tachycardia
• Myocardial infarction (rare, with excessive doses in CAD patients)
• Heart failure exacerbation
• Cardiovascular collapse (massive overdose)

Bone Effects (Long-term):

• Decreased bone mineral density with chronic overreplacement
• Increased fracture risk, especially in postmenopausal women
• T3 component may have greater bone effects than T4 alone at equivalent doses

Adrenal Crisis:

• Can precipitate adrenal insufficiency in patients with undiagnosed/untreated adrenal dysfunction
• Thyroid hormones increase cortisol metabolism
• Must rule out adrenal insufficiency before initiating therapy

Hyperthyroid Crisis (Thyroid Storm):

• Rare but life-threatening with massive overdose
• Fever, tachycardia, delirium, cardiovascular collapse
• Requires emergency treatment

T3-Specific Concerns

The liothyronine component in liotrix creates additional considerations:

Peak-Related Symptoms:

• Symptoms occurring 2-4 hours post-dose suggest T3 peaks
• Palpitations, anxiety, tremor during this window
• May be managed by splitting doses (off-label) or switching to T4 monotherapy

Greater Potency:

• T3 is 3-5 times more potent than T4 microgram-for-microgram
• Narrow therapeutic window
• Small dose changes have greater clinical impact

Fluctuating Levels:

• Serum T3 varies more throughout the day than with T4 monotherapy
• May contribute to variable symptom control

Hypersensitivity Reactions

Rare allergic reactions:

• Typically to inactive ingredients (dyes, fillers)
• Urticaria, rash, pruritus
• Angioedema (rare)
• True allergy to thyroid hormone molecule extremely rare

Effects by Population

Elderly:

• Higher risk of cardiovascular complications
• Atrial fibrillation risk increased
• Start low, titrate slowly

Cardiac Disease:

• Angina may worsen with any thyroid hormone
• Arrhythmia risk elevated
• Heart failure may decompensate

Psychiatric History:

• May exacerbate anxiety disorders
• Can precipitate manic episodes in bipolar disorder

7. Drug Interactions

Liotrix interacts with numerous medications through various mechanisms affecting absorption, metabolism, protein binding, and pharmacodynamic effects.

Absorption Interactions

Substances That Decrease Thyroid Hormone Absorption:

Metabolism Interactions

Drugs That Increase Thyroid Hormone Metabolism:

Drugs That Decrease T4 to T3 Conversion:

Protein Binding Interactions

Drugs Affecting TBG Levels:

Drugs Causing TBG Displacement:

Pharmacodynamic Interactions

Anticoagulants:

• Warfarin: Thyroid hormones increase vitamin K-dependent clotting factor catabolism
• Effect: Enhanced anticoagulant effect, increased INR
• Management: Monitor INR closely when initiating/adjusting thyroid therapy
• May need warfarin dose reduction

Cardiac Glycosides:

• Digoxin: Hyperthyroid state increases digoxin clearance and reduces sensitivity
• Effect: May need higher digoxin doses in thyrotoxicosis
• Management: Monitor digoxin levels and clinical response

Sympathomimetics:

• Epinephrine, norepinephrine, decongestants
• Effect: Potentiated cardiovascular effects (additive)
• Management: Use with caution; risk of tachycardia, hypertension

Antidepressants:

• TCAs: Thyroid hormones may enhance antidepressant effect; also increase arrhythmia risk
• SSRIs: Some may affect thyroid metabolism (sertraline)
• Management: Monitor for toxicity; ECG if concerns

Diabetes Medications:

• Insulin: Thyroid excess increases glucose metabolism; may need insulin adjustment
• Oral agents: Similar considerations
• Effect: Hyperthyroid state impairs glucose control
• Management: Monitor blood glucose; adjust diabetes medications

Ketamine:

• Combination may cause hypertension and tachycardia
• Caution with anesthesia in hyperthyroid patients

Specific Drug Combination Considerations

Amiodarone:

• Contains ~37% iodine by weight
• Can cause both hypo- and hyperthyroidism
• Inhibits T4 to T3 conversion
• Complex management required

Lithium:

• Can cause hypothyroidism (up to 20% of patients)
• May interfere with thyroid hormone release
• Patients on lithium may need thyroid supplementation

Iodine-Containing Agents:

• Radiographic contrast: Transient thyroid dysfunction possible
• Amiodarone: See above
• Kelp/seaweed supplements: Variable iodine content

8. Contraindications

Absolute Contraindications

1. Uncorrected Adrenal Insufficiency

• Rationale: Thyroid hormones increase cortisol metabolism; initiating thyroid replacement in adrenal insufficiency can precipitate adrenal crisis
• Required Action: Diagnose and treat adrenal insufficiency with glucocorticoids BEFORE starting thyroid hormone
• Testing: Morning cortisol, ACTH stimulation test if indicated

2. Untreated Thyrotoxicosis

• Rationale: Additional thyroid hormone would worsen hyperthyroid state
• Clinical Note: Liotrix is for hypothyroidism, not thyrotoxicosis treatment

3. Hypersensitivity

• True allergy to levothyroxine or liothyronine (extremely rare)
• Hypersensitivity to excipients/inactive ingredients (more common)

4. Acute Myocardial Infarction

• Rationale: Thyroid hormones increase myocardial oxygen demand
• Exception: If MI is complicated by or causes hypothyroidism, careful treatment may be indicated with cardiology guidance
• Timing: Generally defer initiation until cardiac status stabilized

Relative Contraindications (Use with Extreme Caution)

1. Cardiovascular Disease

• Coronary artery disease
• Angina pectoris
• History of myocardial infarction
• Heart failure
• Arrhythmias (especially atrial fibrillation)
• Management: Start at lowest dose; slow titration; close monitoring

2. Elderly Patients (>65 years)

• Higher prevalence of occult cardiac disease
• Increased sensitivity to thyroid hormones
• Higher atrial fibrillation risk with overreplacement
• Management: Start low (Thyrolar-¼), titrate slowly

3. Long-standing or Severe Hypothyroidism

• Prolonged hypothyroidism causes cardiovascular adaptation
• Rapid correction can cause cardiac stress
• Management: Very gradual dose titration over months

4. Diabetes Mellitus

• Thyroid hormones affect glucose metabolism
• Starting/adjusting thyroid therapy may alter insulin requirements
• Management: Close glucose monitoring; adjust diabetes medications

5. Osteoporosis

• Excessive thyroid hormone accelerates bone loss
• Postmenopausal women at highest risk
• Management: Avoid overreplacement; monitor TSH to ensure not suppressed unless indicated

6. Autonomic Dysfunction

• Patients may have exaggerated cardiovascular responses
• Management: Careful monitoring

Precautions and Warnings

TSH Suppression in Non-Thyroid Cancer Patients:

• Avoid TSH suppression below normal range unless treating thyroid cancer
• Suppressed TSH associated with:
  • Increased atrial fibrillation risk
  • Accelerated bone loss
  • Potential cardiovascular mortality increase

Use in Obesity:

• Thyroid hormones should NOT be used for weight loss in euthyroid individuals
• Such use is ineffective (feedback suppresses endogenous production)
• Large doses cause serious or life-threatening toxicity

Coexisting Conditions:

• Pituitary insufficiency may coexist with hypothyroidism
• Screen for adrenal and gonadal insufficiency
• Treat adrenal insufficiency before thyroid insufficiency

9. Special Populations

Pregnancy

FDA Pregnancy Category A (when used appropriately for hypothyroidism)

Physiological Changes:

• Thyroid hormone requirements increase 25-50% during pregnancy
• Increased TBG from estrogen effect
• Increased plasma volume
• Placental metabolism of T4

Management Considerations:

• Levothyroxine monotherapy strongly preferred over combination products
• T3 crosses placenta less readily than T4
• Fetal brain development depends primarily on T4 (converted locally to T3)
• Direct T3 administration may not provide optimal fetal thyroid status

If Combination Therapy Used:

• Close TSH monitoring (every 4 weeks first half of pregnancy)
• Maintain TSH in trimester-specific reference ranges
• Most guidelines recommend against routine combination therapy in pregnancy

Postpartum:

• Requirements typically decrease after delivery
• Dose adjustment usually needed within 4-6 weeks postpartum
• Monitor for postpartum thyroiditis

Lactation

• Thyroid hormones are excreted in breast milk in minimal amounts
• Levothyroxine and liothyronine compatible with breastfeeding
• Adequate maternal thyroid status important for lactation
• No dose adjustment needed for breastfeeding

Pediatric

General Recommendation:

• Levothyroxine monotherapy is standard of care
• Liotrix was NOT routinely used in pediatric populations
• T3 fluctuations potentially more problematic in developing children

Congenital Hypothyroidism:

• Early levothyroxine treatment critical for neurodevelopment
• Liotrix not recommended for congenital hypothyroidism

If Combination Therapy Considered:

• Weight-based dosing
• Very close monitoring
• Not FDA-approved specifically for pediatric use

Geriatric

Age-Related Considerations:

• Decreased T4 clearance (may need lower doses)
• Increased cardiovascular disease prevalence
• Higher risk of atrial fibrillation with overreplacement
• Greater sensitivity to thyroid hormones

Dosing:

• Start at lowest available dose (Thyrolar-¼ was 12.5/3.1 mcg)
• Increase slowly (every 6-8 weeks)
• TSH targets may be slightly higher in elderly (up to 4-5 mIU/L acceptable in some cases)

Monitoring:

• Cardiovascular symptoms with each dose change
• Heart rate and rhythm
• Bone density if on long-term therapy

Renal Impairment

• Minimal dose adjustment typically required
• Thyroid hormone clearance not primarily renal
• Binding proteins may be altered in nephrotic syndrome
• Monitor clinically and with TSH

Hepatic Impairment

• Liver disease may affect TBG levels
• Decreased TBG → lower total T4 requirements
• Conversion of T4 to T3 may be impaired in severe liver disease
• Liotrix theoretically useful if T4→T3 conversion impaired (though not evidence-based)
• Monitor closely; adjust based on free hormone levels and TSH

Cardiac Disease

Critical Population:

• Thyroid hormones increase myocardial oxygen demand
• Risk of angina, arrhythmias, heart failure exacerbation
• T3 component causes more acute cardiovascular effects than T4 alone

Management:

• Cardiology consultation often appropriate
• Start at very low doses
• Extremely slow titration
• May accept suboptimal TSH to limit cardiovascular risk
• Consider T4 monotherapy instead (less acute effects)

Adrenal Insufficiency

• MUST be diagnosed and treated before thyroid therapy
• Thyroid hormones increase cortisol clearance
• Can precipitate adrenal crisis if cortisol deficiency untreated
• Start glucocorticoid replacement first

10. Monitoring Parameters

Baseline Assessment

Before Initiating Liotrix:

1. TSH: Confirm hypothyroidism diagnosis
2. Free T4: Assess severity
3. Free T3: Optional; helps if conversion defect suspected
4. TPO Antibodies: If autoimmune thyroiditis suspected
5. Morning Cortisol: Rule out adrenal insufficiency (especially if TSH very high)
6. ECG: Baseline in cardiac patients or elderly
7. Lipid Panel: Hypothyroidism causes dyslipidemia; will improve with treatment
8. Weight: Baseline for monitoring

Monitoring During Dose Titration

Frequency:

• TSH every 4-6 weeks until stable
• Free T4 with TSH if needed for interpretation
• Free T3 if symptoms suggest over/underreplacement despite normal TSH

Clinical Assessment:

• Hypothyroid symptoms: fatigue, cold intolerance, constipation, cognitive slowing
• Hyperthyroid symptoms: palpitations, tremor, anxiety, heat intolerance, diarrhea
• Weight changes
• Heart rate and blood pressure

Laboratory Targets:

• TSH: 0.5-2.5 mIU/L for most patients (individualized)
• TSH <0.1 mIU/L: Only for thyroid cancer suppression
• Free T4: Mid-normal range
• Free T3: May be elevated post-dose; measure pre-dose or 8+ hours post-dose

Long-term Monitoring

Stable Patients:

• TSH annually (minimum)
• More frequent if dose changes, pregnancy, or new medications

Free T3 Considerations:

• With liotrix, T3 levels fluctuate throughout the day
• Timing of blood draw relative to dose affects results
• Pre-dose (trough) measurements most useful
• Peak levels (2-4 hours post-dose) may exceed normal range even with appropriate dosing

Special Monitoring Situations

Cardiovascular Disease:

• Heart rate and rhythm
• Symptoms: chest pain, dyspnea, palpitations
• ECG if arrhythmia suspected
• Consider cardiology consultation

Bone Health (Long-term Therapy):

• DEXA scan at baseline if osteoporosis risk factors
• Repeat every 2 years if postmenopausal or on suppressive doses
• Avoid overreplacement (suppressed TSH) unless indicated

Pregnancy:

• TSH every 4 weeks during first half of pregnancy
• Every 6-8 weeks during second half
• 4-6 weeks postpartum
• Trimester-specific TSH reference ranges

Thyroid Cancer (Suppressive Therapy):

• TSH suppression goals based on risk stratification
• High risk: TSH <0.1 mIU/L
• Low risk: TSH 0.5-2.0 mIU/L (after initial treatment)
• Thyroglobulin levels for recurrence monitoring

Laboratory Interpretation Caveats

TSH:

• Gold standard for monitoring in primary hypothyroidism
• May be misleading in secondary/tertiary hypothyroidism
• Affected by: non-thyroidal illness, medications (steroids, dopamine), biotin supplements

Free T4:

• Direct measurement methods vary between labs
• Useful adjunct to TSH

Free T3:

• Highly variable with liotrix due to direct T3 dosing
• Timing-dependent interpretation critical
• Peak values may be supra-physiological
• Trough values better reflect adequacy

Total T4/T3:

• Affected by binding protein changes
• Less useful than free hormone measurements
• May be misleading with estrogen therapy, liver disease, nephrotic syndrome

Biotin Interference:

• High-dose biotin supplements interfere with many thyroid assays
• Can cause falsely low TSH, falsely high T4/T3 (streptavidin-biotin assays)
• Recommend stopping biotin 48-72 hours before thyroid labs

11. Cost and Availability

Current US Availability Status

CRITICAL: Thyrolar is DISCONTINUED in the United States as of December 2018.

Discontinuation Details:

• Date: December 2018
• Manufacturer: Allergan (now part of AbbVie)
• Reason: Business decision (not safety-related)
• Prior Manufacturer History: Forest Pharmaceuticals → Actavis → Allergan
• Generic Versions: None were available; Thyrolar was marketed only as a brand product

No Liotrix Products Available in US Market:

• No generic liotrix approved in the US
• No alternative branded liotrix products
• Manufacturer has not announced plans to resume production
• No other company has filed to produce liotrix in the US

International Availability

Novothyral (Europe):

• Manufacturer: Merck KGaA (Germany)
• Status: Still available in European markets
• Formulations:
  • Novothyral 75/15 (75 mcg T4 + 15 mcg T3)
  • Novothyral 100/20 (100 mcg T4 + 20 mcg T3)
• Ratio: 5:1 (differs from US Thyrolar's 4:1)
• Countries: Germany, other European Union nations

Note on Importation:

• Personal importation from foreign countries is legally complex
• FDA does not routinely approve personal importation
• Quality and authenticity concerns with international pharmacy purchases
• Some specialty pharmacies may facilitate access (consult healthcare provider)

Historical Pricing (US, Prior to Discontinuation)

Brand Thyrolar (2018 pricing, approximate):

Insurance Coverage (Historical):

• Often covered by insurance with prior authorization
• Tier 3 (non-preferred brand) on most formularies
• Required documentation of T4 monotherapy failure

Current Alternatives and Their Costs

For Patients Requiring Combination Therapy:

Since liotrix is unavailable, patients must use separate products:

1. Levothyroxine (T4) + Liothyronine (T3) Separately:

Combined Cost: $20-350/month depending on brand vs. generic choices

2. Desiccated Thyroid Extract (NDT):

• Armour Thyroid, NP Thyroid, Nature-Throid (if available)
• Contains T4 and T3 in ~4:1 ratio (similar to liotrix)
• Cost: $30-80/month (generic) to $80-150/month (brand)
• Note: NDT products face FDA regulatory uncertainty (see Armour Thyroid paper)

3. Compounded Thyroid Preparations:

• Custom T4/T3 ratios from compounding pharmacies
• Cost: $50-150/month
• Quality and consistency concerns
• Not FDA-approved; regulatory oversight varies

Insurance and Formulary Considerations

Separate T4 + T3 Products:

• Levothyroxine generics: Widely covered, low copays
• Liothyronine generic: Usually covered; may require prior authorization
• Cytomel brand: Often requires prior authorization; higher copay

Documentation for Coverage:

• Diagnosis of hypothyroidism
• Trial of T4 monotherapy
• Documented persistent symptoms despite optimal TSH
• Some insurers require endocrinologist recommendation

Transition Options for Former Liotrix Users

Recommended Approaches:

1. Levothyroxine Monotherapy (First-Line):

   • Most patients do well on T4 alone
   • Conversion: Thyrolar-1 (50/12.5) → approximately 75-100 mcg levothyroxine
   • Monitor TSH and symptoms

2. Separate T4 + T3 Products:

   • Allows individualized ratio adjustment
   • Example: 75 mcg levothyroxine + 5-10 mcg liothyronine
   • More flexibility than fixed-ratio products

3. Desiccated Thyroid Extract:

   • Similar T4:T3 ratio to liotrix
   • Natural source (porcine)
   • Availability concerns (FDA regulatory issues)

12. Clinical Evidence Summary

Rationale for Combination Therapy Development

Theoretical Basis:

• Peripheral T4→T3 conversion may be impaired in some patients
• Deiodinase polymorphisms (DIO1, DIO2) affect conversion efficiency
• Direct T3 supplementation bypasses conversion requirement
• Some patients report improved well-being with combination therapy

Historical Context:

• Liotrix developed in 1956 before modern understanding of thyroid physiology
• 4:1 ratio based on early estimates of thyroid gland secretion
• Subsequent research showed physiological ratio is approximately 14:1 to 17:1 T4:T3
• The 4:1 ratio provides relatively more T3 than physiological secretion

Clinical Trials: Combination vs. Monotherapy

Systematic Reviews and Meta-Analyses:

Multiple high-quality systematic reviews have evaluated T4/T3 combination therapy versus T4 monotherapy:

Grozinsky-Glasberg et al. (2006):

• Meta-analysis of 11 RCTs
• No significant difference in:
  • Bodily pain, depression, anxiety
  • Fatigue, quality of life
  • Body weight, lipid levels
• Conclusion: No evidence to support routine combination therapy

Joffe et al. (2007):

• Meta-analysis of 9 RCTs
• Primary outcome: Mood and well-being
• No significant benefit of combination therapy
• Similar conclusions across different dosing ratios

Wiersinga et al. (2012) - ETA Guidelines:

• Comprehensive review for European Thyroid Association
• Concluded insufficient evidence to recommend combination therapy
• Acknowledged subset of patients may benefit; selection criteria unclear

2012 ETA/ATA Joint Statement:

• No consistent evidence of superiority for combination therapy
• Not recommended as routine treatment
• May be considered in selected patients after thorough discussion

Liotrix-Specific Studies

Limited Direct Evidence:

• Most combination therapy trials used separate T4 + T3 products
• Few studies specifically evaluated liotrix (Thyrolar)
• Fixed 4:1 ratio limits applicability of other combination therapy data

Hypothesized Advantages of Fixed Ratio:

• Simplicity of single tablet
• Consistent T4:T3 ratio
• Potential compliance benefits

Disadvantages:

• Cannot individualize ratio
• 4:1 ratio non-physiological
• Peak T3 effects unavoidable

Deiodinase Polymorphism Research

DIO2 Gene Variants:

• Thr92Ala polymorphism in DIO2 gene
• Hypothesized to impair T4→T3 conversion
• Some studies suggested these patients might benefit from combination therapy
• 2017 Study (Panicker et al.): DIO2 genotype did NOT predict response to combination therapy
• Current evidence does not support genotype-based prescribing

Quality of Life Studies

Patient-Reported Outcomes:

• Some observational studies show patient preference for combination therapy
• Placebo effects and expectations may contribute
• Blinded RCTs generally do not confirm objective benefits

Persistent Symptoms Despite Normal TSH:

• ~5-10% of hypothyroid patients report ongoing symptoms on T4 monotherapy
• Causes multifactorial:
  • Autoimmune inflammation (thyroiditis-associated)
  • Non-thyroidal illness
  • Comorbid conditions (depression, fibromyalgia)
  • Inadequate dosing or absorption issues
• Combination therapy may help some, but selection criteria undefined

Guidelines Recommendations

American Thyroid Association (ATA) 2014:

• Levothyroxine monotherapy remains standard of care
• Combination therapy not routinely recommended
• May be considered as experimental/trial in selected patients
• T4:T3 ratio of 13:1 to 20:1 more physiological than 4:1

European Thyroid Association (ETA) 2012:

• Similar conclusions to ATA
• Insufficient evidence for routine combination therapy
• Individual trial may be reasonable with informed consent

AACE/ACE 2012:

• Levothyroxine is treatment of choice
• Combination therapy not recommended based on available evidence

Summary of Evidence

Bottom Line:

• No high-quality evidence supports routine use of combination therapy
• Liotrix's fixed 4:1 ratio is non-physiological
• Individual patients may report benefit, but this is not consistently reproducible
• Product discontinuation reflects limited clinical demand and market

13. Comparison with Alternatives

Levothyroxine Monotherapy

The Standard of Care:

Advantages of Levothyroxine:

• Long track record of safety and efficacy
• Stable serum hormone levels
• Low cost with generic availability
• Well-understood pharmacokinetics
• Easily titratable with multiple strengths

When Levothyroxine May Fall Short:

• Persistent symptoms despite optimal TSH
• Possible impaired T4→T3 conversion
• Patient preference for combination therapy

Separate Levothyroxine + Liothyronine

Individualized Combination Therapy:

Advantages of Separate Products:

• Customize T4:T3 ratio to individual needs
• Adjust each component independently
• Can use sustained-release T3 formulations (compounded)
• More physiological ratios achievable (13:1 to 20:1)

Disadvantages:

• More complex regimen (multiple tablets)
• T3 fluctuations unless doses split
• Higher cost if using brand products

Desiccated Thyroid Extract (NDT)

Natural Thyroid Hormone:

Advantages of NDT:

• Similar T4:T3 ratio to liotrix
• Contains additional thyroid hormones (unclear significance)
• Some patients prefer "natural" source
• Long history of clinical use

Disadvantages:

• Variable T3 content between batches possible
• Not FDA-approved; faces regulatory uncertainty
• Animal-derived (concern for some patients)
• Supply disruptions possible

Compounded Thyroid Preparations

Custom Formulations:

Advantages of Compounding:

• Any desired ratio possible
• Sustained-release T3 formulations
• Avoid specific inactive ingredients (allergies)
• Combination with other hormones possible

Disadvantages:

• Quality varies by pharmacy
• No FDA oversight of compounding
• Potency concerns
• Generally not covered by insurance

Comparison Summary Table

Transitioning from Liotrix

For Former Thyrolar Users:

1. Most Common Transition: Levothyroxine monotherapy

   • Equivalent dose: Thyrolar-1 → ~75-100 mcg levothyroxine
   • Many patients do well without T3 supplementation
   • Trial period of 3-6 months recommended

2. If Symptoms Persist: Add liothyronine separately

   • Start with low dose (5 mcg once or twice daily)
   • Target more physiological ratio (13:1 to 20:1)
   • Monitor for T3 peak symptoms

3. Alternative: Desiccated thyroid extract

   • Similar ratio to former liotrix
   • Note regulatory uncertainties

14. Storage and Handling

Storage Requirements (Historical Product Information)

Thyrolar Storage Conditions:

• Temperature: Store at controlled room temperature, 20-25°C (68-77°F)
• Excursions permitted: 15-30°C (59-86°F)
• Humidity: Protect from excessive moisture
• Light: Protect from light; store in original container
• Container: Keep in tightly closed container

Stability Considerations

Thyroid Hormone Stability:

• Both levothyroxine and liothyronine are relatively stable compounds
• T3 component may be slightly more susceptible to degradation than T4
• Heat, humidity, and light can accelerate degradation
• Potency loss can occur with improper storage

Signs of Degradation:

• Color change in tablets
• Unusual odor
• Tablet crumbling or disintegration
• Reduced clinical efficacy

European Product (Novothyral) Storage

For Patients Accessing International Supply:

• Similar storage requirements to US product
• Consult specific product labeling
• Consider temperature during shipping/importation
• Verify cold chain maintained if applicable

Handling Precautions

Healthcare Provider Handling:

• Standard pharmaceutical handling procedures
• No special precautions required for intact tablets
• Avoid crushing if possible (preserves coating)

Patient Handling:

• Wash hands before and after handling
• Take immediately after removing from container
• Do not transfer to other containers (stability concerns)
• Keep out of reach of children

Disposal

Proper Disposal Methods:

• Do not flush medications down toilet
• Do not pour down drain
• Use medication take-back programs when available
• If no take-back available: Mix with undesirable substance (coffee grounds, dirt) and place in sealed container before household trash
• Follow local regulations for pharmaceutical disposal

Supply Chain Considerations (For Imported Products)

If Obtaining from International Sources:

• Verify pharmacy legitimacy
• Confirm proper storage during shipping
• Check expiration dates carefully
• Be aware of counterfeiting risks
• Temperature-controlled shipping preferred

15. References

Primary Literature

1. American Thyroid Association (ATA) Guidelines Task Force. Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670-1751.

2. Wiersinga WM, Duntas L, Fadeyev V, et al. 2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism. Eur Thyroid J. 2012;1(2):55-71.

3. Grozinsky-Glasberg S, Fraser A, Nahshoni E, et al. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2006;91(7):2592-2599.

4. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-1751.

5. Biondi B, Wartofsky L. Combination treatment with T4 and T3: toward personalized replacement therapy in hypothyroidism? J Clin Endocrinol Metab. 2012;97(7):2256-2271.

6. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009;94(5):1623-1629.

7. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(6):988-1028.

8. Saravanan P, Chau WF, Roberts N, et al. Psychological well-being in patients on 'adequate' doses of L-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf). 2002;57(5):577-585.

9. Appelhof BC, Fliers E, Wekking EM, et al. Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial. J Clin Endocrinol Metab. 2005;90(5):2666-2674.

10. Escobar-Morreale HF, Botella-Carretero JI, Gómez-Bueno M, et al. Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med. 2005;142(6):412-424.

Drug Information Resources

11. Thyrolar (liotrix) [package insert]. New York, NY: Forest Pharmaceuticals, Inc.; 2014 (discontinued product).

12. Lexi-Drugs. Liotrix. Lexicomp. Wolters Kluwer Health, Inc. Accessed December 2025.

13. AHFS Drug Information. Liotrix. American Society of Health-System Pharmacists. Bethesda, MD.

14. Novothyral (levothyroxine/liothyronine) Summary of Product Characteristics. Merck KGaA. Darmstadt, Germany.

Regulatory Documents

15. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Liotrix listings (historical).

16. FDA Drug Shortages Database. Thyrolar discontinuation notice. December 2018.

Review Articles and Guidelines

17. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006;116(10):2571-2579.

18. Hoermann R, Midgley JE, Larisch R, Dietrich JW. Homeostatic Control of the Thyroid-Pituitary Axis: Perspectives for Diagnosis and Treatment. Front Endocrinol. 2015;6:177.

19. Okosieme O, Gilbert J, Abraham P, et al. Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee. Clin Endocrinol (Oxf). 2016;84(6):799-808.

20. Peterson SJ, Cappola AR, Castro MR, et al. An Online Survey of Hypothyroid Patients Demonstrates Prominent Dissatisfaction. Thyroid. 2018;28(6):707-721.

Pharmacology References

21. Bianco AC, Salvatore D, Gereben B, et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002;23(1):38-89.

22. Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev. 2001;81(3):1097-1142.

23. Brent GA. Mechanisms of thyroid hormone action. J Clin Invest. 2012;122(9):3035-3043.

24. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev. 2010;31(2):139-170.

25. Groeneweg S, Visser WE, Visser TJ. Disorder of thyroid hormone transport into the tissues. Best Pract Res Clin Endocrinol Metab. 2017;31(2):241-253.

Document Footer

Document Completion: 2025-12-26 Status: PAPER 48 OF 76 COMPLETE Next Paper: #49 - Prednisone

Important Notice: Liotrix (Thyrolar) is DISCONTINUED in the United States as of December 2018. This document is provided for historical reference and to assist healthcare providers and patients in understanding this medication and transitioning to available alternatives. For current thyroid replacement therapy, consult current guidelines recommending levothyroxine monotherapy as first-line treatment.

This research paper is part of a comprehensive HRT/hormone product documentation project for Epiq Aminos clinical reference materials.